• CVS Health reached a global settlement with the FTC, ending litigation and investigations tied to its PBM and affiliated pharmacy operations.
• Deal targets rebate practices, pharmacy network contracting, spread pricing, and vertical integration concerns flagged by regulators.
• Commercial client offerings will shift toward net-cost member cost sharing, point-of-sale rebate passthrough, reduced rebate guarantees, and enhanced pricing disclosures.
• Settlement includes an insulin out-of-pocket cap of USD 25 per month for members under a new offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE03484) on July 14, 2026, and is solely responsible for the information contained therein.